TAM Receptor

Tyro3; Axl; Mer

TAM receptors, comprising of Tyro3, Axl and Mertk receptors, are receptor tyrosine kinases (RTKs) that are expressed by multiple immune cells including NK cells. The TAM family of receptors and their ligands Gas6 and Protein S (PROS1) are required for the optimal phagocytosis of apoptotic cells in the mature immune, nervous, and reproductive systems.

TAMs are three homologous type I receptor-tyrosine kinases that are activated by endogenous ligands, PROS1 and GAS6. These ligands can either activate TAMs as soluble factors, or, in turn, opsonize phosphatidylserine (PS) on apoptotic cells (ACs) and serve as bridging molecules between ACs and TAMs. Abnormal expression and activation of TAMs have been implicated in promoting proliferation and survival of cancer cells, as well as in suppressing anti-tumor immunity.

TAM Receptor Inhibitors

2-D08

Cat. No.: HY-114166

2-D08 is a cell permeable, mechanistically unique inhibitor of protein **SUMOylation**. 2-D08 also inhibits **Axl** with an IC_{50} of 0.49 nM.



Purity: 98.44%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Axl-IN-3

Cat. No.: HY-144706

Axl-IN-3 is a potent, selective and orally active **AXL kinase** inhibitor with an IC_{50} of 41.5 nM. Axl-IN-3 has lower inhibition of other kinases.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Axl-IN-4

Cat. No.: HY-144708

Axl-IN-4 (Compound 24) is an **AXL kinase** inhibitor with an IC_{50} of 28.8 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Axl-IN-5

Cat. No.: HY-146596

Axl-IN-5 (compound 1) is a **AXL** inhibitor with an IC_{50} of 283 nM. Axl-IN-5 has anticancer effects.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Axl-IN-6

Cat. No.: HY-146615

Axl-IN-6 (compound 14) is an orally active and potent **AXL** inhibitor. Axl-IN-6 is well tolerated and significantly inhibits the tumor growth in MV-4-11 subcutaneous xenograft model.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

AZ14145845

Cat. No.: HY-132893

AZ14145845 is a highly selective type I1/2 dual **Mer/Axl** kinase inhibitor with in vivo efficacy.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Bemcentinib

(R428; BGB324)

Cat. No.: HY-15150

Bemcentinib (R428) is a potent and selective inhibitor of **Axl** with an IC_{50} of 14 nM.



Purity: 99.95%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

BMS 777607

(BMS 817378)

Cat. No.: HY-12076

BMS 777607 (BMS 817378) is a **Met-related** inhibitor for **c-Met**, **Axl**, **Ron** and **Tyro3** with IC_{50}s of 3.9 nM, 1.1 nM, 1.8 nM and 4.3 nM, respectively, and 40-fold more selective for Met-related targets than Lck, VEGFR-2, and TrkA/B, with more than 500-fold greater selectivity...



Purity: 99.04%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Cabozantinib

(XL184; BMS-907351)

Cat. No.: HY-13016

Cabozantinib is a potent multiple receptor tyrosine kinases (RTKs) inhibitor that inhibits **VEGFR2**, **c-Met**, **Kit**, **Axl** and **Flt3** with IC_{50}s of 0.035, 1.3, 4.6, 7 and 11.3 nM, respectively.



Purity: 99.96%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

Cabozantinib-d4

(XL184-d4; BMS-907351-d4)

Cat. No.: HY-13016S1

Cabozantinib-d4 is deuterium labeled Cabozantinib. Cabozantinib is a potent multiple receptor tyrosine kinases (RTKs) inhibitor that inhibits VEGFR2, c-Met, Kit, Axl and Flt3 with IC50s of 0.035, 1.3, 4.6, 7 and 11.3 nM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Tel: 609-228-6898 Fax: 609-228-5909 Email: sales@MedChemExpress.com

Cabozantinib-d6

Cat. No.: HY-13016S

Cabozantinib-d6 (XL184-d6) is the deuterium labeled Cabozantinib. Cabozantinib is a potent multiple receptor tyrosine kinases (RTKs) inhibitor that inhibits **VEGFR2**, **c-Met**, **Kit**, **Axl** and **Flt3** with IC_{50}s of 0.035, 1.3, 4.6, 7 and 11.3 nM, respectively.



Purity: 98.14%
Clinical Data: No Development Reported
Size: 2.5 mg, 1 mg, 5 mg, 10 mg

CEP-40783

(RXDX-106) Cat. No.: HY-100946

CEP-40783 is a potent, selective and orally available inhibitor of **AXL** and **c-Met** with IC_{50} values of 7 nM and 12 nM, respectively.



Purity: 99.22%
Clinical Data: Phase 1
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg, 200 mg, 500 mg, 1 g

DS-1205b free base

Cat. No.: HY-114357A

DS-1205b free base is a potent and selective inhibitor of **AXL kinase**, with an IC_{50} of 1.3 nM. DS-1205b free base also inhibits **MER**, **MET**, and **TRKA**, with IC_{50}s of 63, 104, and 407 nM, respectively. DS-1205b free base can inhibit cell migration in vitro and tumor growth in vivo.



Purity: 99.92%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg

Dubermatinib

(TP-0903) Cat. No.: HY-12963

Dubermatinib (TP-0903) is a potent and selective **Axl** receptor tyrosine kinase inhibitor with an IC_{50} value of 27 nM.



Purity: 99.82%
Clinical Data: Phase 1
Size: 5 mg, 10 mg, 50 mg, 100 mg

Gilteritinib

(ASP2215) Cat. No.: HY-12432

Gilteritinib (ASP2215) is a potent and ATP-competitive **FLT3/AXL** inhibitor with IC_{50}s of 0.29 nM/0.73 nM, respectively.



Purity: 99.55%
Clinical Data: Launched
Size: 5 mg, 10 mg, 50 mg, 100 mg

Gilteritinib hemifumarate

(ASP2215 hemifumarate) Cat. No.: HY-12432A

Gilteritinib (ASP2215) hemifumarate is a potent and ATP-competitive **FLT3/AXL** inhibitor with IC_{50} of 0.29 nM/0.73 nM, respectively.



Purity: 99.96%
Clinical Data: Launched
Size: 5 mg, 10 mg, 50 mg, 100 mg

Gilteritinib-d3

(ASP2215-d3) Cat. No.: HY-12432S

Gilteritinib-d3 (ASP2215-d3) is the deuterium labeled Gilteritinib. Gilteritinib (ASP2215) is a potent and ATP-competitive **FLT3/AXL** inhibitor with IC_{50}s of 0.29 nM/0.73 nM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Gilteritinib-d8

(ASP2215-d8) Cat. No.: HY-12432S1

Gilteritinib-d8 is deuterium labeled Gilteritinib. Gilteritinib (ASP2215) is a potent and ATP-competitive FLT3/AXL inhibitor with IC50s of 0.29 nM/0.73 nM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Glesatinib

(MGCD265) Cat. No.: HY-19642

Glesatinib (MGCD265) is an orally active, potent **MET/SMO** dual inhibitor. Glesatinib, a tyrosine kinase inhibitor, antagonizes P-glycoprotein (P-gp) mediated multidrug resistance (MDR) in non-small cell lung cancer (NSCLC).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Glesatinib hydrochloride

(MGCD265 hydrochloride) Cat. No.: HY-19642A

Glesatinib hydrochloride (MGCD265 hydrochloride) is an orally active, potent **MET/SMO** dual inhibitor. Glesatinib hydrochloride, a tyrosine kinase inhibitor, antagonizes P-glycoprotein (P-gp) mediated multidrug resistance (MDR) in non-small cell lung cancer (NSCLC).



Purity: 98.25%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

LDC1267

Cat. No.: HY-12494

LDC1267 is a highly selective **TAM (Tyro3, Axl and Mer)** kinase inhibitor with IC_{50}s of <5 nM/8 nM/29 nM for Tyro3,Axl and Mer respectively.



Purity: 99.39%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Multi-kinase-IN-1

Cat. No.: HY-146014

Multi-kinase-IN-1 (Compound 11k) is a potent **kinase** inhibitor with antitumor activity. Multi-kinase-IN-1 induces cell **apoptosis**, and can be studied for **colorectal cancer**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Ningetinib

Cat. No.: HY-107145A

Ningetinib is a potent, orally bioavailable small molecule tyrosine kinase inhibitor (**TKI**) with IC_{50}s of 6.7, 1.9 and <1.0 nM for **c-Met**, **VEGFR2** and **Axl**, respectively.



Purity: 99.79%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Ningetinib Tosylate

Cat. No.: HY-107145

Ningetinib Tosylate is a potent, orally bioavailable small molecule tyrosine kinase inhibitor (**TKI**) with IC_{50}s of 6.7, 1.9 and <1.0 nM for **c-Met**, **VEGFR2** and **Axl**, respectively.



Purity: 99.92%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

NPS-1034

Cat. No.: HY-100509

NPS-1034 is a dual inhibitor of **AXL** and **MET** with IC_{50}s of 10.3 and 48 nM, respectively.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

ONO-7475

Cat. No.: HY-114358

ONO-7475 is a potent, selective, and orally active **Axl/Mer** inhibitor with IC_{50} values of 0.7 nM and 1.0 nM, respectively. ONO-7475 sensitizes AXL-overexpressing EGFR-mutant NSCLC cells to the EGFR-TKIs, suppresses the emergence and maintenance of tolerant cells.



Purity: 99.38%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

PROTAC Axl Degrader 1

Cat. No.: HY-144624

PROTAC Axl Degrader 1 is a potent and selective **PROTAC Axl** degrader with an IC_{50} of 0.92 μM. PROTAC Axl Degrader 1 shows anti-proliferation activity, anti-migration activity in vitro. PROTAC Axl Degrader 1 induces **mehuosis**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PROTAC Axl Degrader 2

Cat. No.: HY-144627

PROTAC Axl Degrader 2 is a potent and selective **PROTAC Axl** degrader with an IC_{50} of 1.61 μM. PROTAC Axl Degrader 2 shows anti-proliferation activity, anti-migration activity in vitro. PROTAC Axl Degrader 2 induces **mehuosis**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

R916562

Cat. No.: HY-104075

R916562 is an orally active and selective **Axl/VEGF-R2** inhibitor with IC_{50}s of 136 nM and 24 nM, respectively. R916562 has anti-angiogenesis and anti-metastasis.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

RU-301

Cat. No.: HY-119039

RU-301 is a pan-**TAM** receptor inhibitor, exerts pan-TAM inhibitory activity by binding at the interface between Gas6 and the Ig1 domain of the respective TAMs with K_d and IC_{50} values of 12 μM and 10 μM, respectively.



Purity: 99.73%
Clinical Data:
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

RU-302

Cat. No.: HY-124066

RU-302 is a pan **TAM** inhibitor that blocks the interface between the TAM Ig1 ectodomain and the Gas6 Lg domain. RU-302 effectively blocks Gas6-inducible **Axl** receptor activation with a low micromolar IC_{50} in cell assays, and suppresses lung cancer tumor growth.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

SGI-7079

Cat. No.: HY-12964

SGI-7079 is a potent and ATP-competitive **Axl** inhibitor, significantly inhibits the proliferation of SUM149 or KPL-4 cells with an IC_{50} of 0.43 or 0.16 μM, respectively.



Purity: 99.65%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

TAM-IN-2

Cat. No.: HY-126216

TAM-IN-2 is a TAM inhibitor extracted from patent US 20170275290 A1, pyrrolotriazine compound 0904.



Purity: 99.87%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

UNC1062

Cat. No.: HY-117548

UNC1062 is a **MERTK**-selective tyrosine kinase inhibitor, reduces activation of MERTK-mediated downstream signaling, induces **apoptosis** in culture, reduces colony formation in soft agar, and inhibits invasion of melanoma cells.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

UNC2250

Cat. No.: HY-15797

UNC2250 is a potent and selective **Mer** inhibitor with an IC_{50} of 1.7 nM, about 160- and 60-fold selectivity over the closely related kinases Axl/Tyro3.



Purity: 99.22%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

UNC2541

Cat. No.: HY-125510

UNC2541 is a potent and Mer tyrosine kinase (**MerTK**)-specific inhibitor, binds in the MerTK ATP pocket, with an IC_{50} of 4.4 nM, more selective over Axl, Tyro3 and Flt3. UNC2541 inhibits phosphorylated MerTK (pMerTK; EC_{50}, 510 nM).



Purity: 99.71%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

UNC2881

Cat. No.: HY-15798

UNC2881 is a potent and specific Mer kinase inhibitor; inhibits steady-state Mer kinase phosphorylation with an IC50 value of 22 nM.



Purity: 99.91%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 500 mg

UNC4203

Cat. No.: HY-124502

UNC4203 is a potent, orally available and highly selective **MERTK** inhibitor, with IC_{50}s of 1.2 nM, 140 nM, 42 nM and 90 nM for MERTK, AXL, TYRO3 and FLT3, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

UNC5293

Cat. No.: HY-132200

UNC5293 is a **MERTK**-selective and potent inhibitor (K_i=190 pM). UNC5293 inhibits MERTK (IC_{50}=0.9 nM) and is more selective over Axl, Tyro3 and Flt3. UNC5293 exhibits excellent mouse PK properties and is used for bone marrow leukemia research.



Purity: 99.31%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

UNC569

Cat. No.: HY-117596

UNC569 is a potent, reversible, ATP-competitive and orally active **Mer kinase** inhibitor with an IC_{50} of 2.9 nM and a K_i of 4.3 nM. UNC569 also inhibits **Axl** and **Tyro3** with IC_{50}s of 37 nM and 48 nM, respectively.



Purity: 98.64%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg

XL092

Cat. No.: HY-138696

XL092 is an orally active, ATP-competitive inhibitor of multiple receptor tyrosine kinases (RTKs) including **MET**, **VEGFR2**, **AXL** and **MER**, with **IC_{50}**s in cell-based assays of 15 nM, 1.6 nM, 3.4 nM, 7.2 nM respectively. XL092 exhibits anti-tumor activity.



Purity: 99.52%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg